ISBN: 9781032291680 - biopharmaceutical informatics: learning to discover developable biotherapeutics (11 resultados)

Condición: As New. Unread book in perfect condition.

Condición: New.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New.

Paperback. Condición: Brand New. 368 pages. 6.14x0.80x9.21 inches. In Stock.

Condición: New. Dr. Sandeep Kumar is currently a Distinguished Fellow (Executive Director) at the department of Computational Science in Moderna Therapeutics, Cambridge, MA where he leads Molecular Design and Modeling team. Sandeep Kumar holds a Ph.D. in Computat.

Taschenbuch. Condición: Neu. Neuware - Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have come up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently: - Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principles - Describes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing them - Details applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacology - Presents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticals - Describes uses of AIML in bispecific and multi-specific formats Dr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs.…

PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Paperback. Condición: new. Paperback. Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have come up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently:Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principlesDescribes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing themDetails applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacologyPresents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticalsDescribes uses of AIML in bispecific and multi-specific formatsDr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs. This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…